135362-69-5

Basic information

• Product Name: 3-(4-Methoxybenzyloxy)-1-propanol
• Synonyms: 3-(4-Methoxybenzyloxy)-1-propanol;3-(4-Methoxyphenylmethoxy)-1-propanol;3-((4-Methoxybenzyl)oxy)propan-1-ol
• CAS NO: 135362-69-5
• Molecular Formula: C₁₁H₁₆O₃
• Molecular Weight: 196.24294
• Mol File: 135362-69-5.mol
• Article Data: 72

Chemical Properties

• Boiling Point: 334.2±22.0 °C(Predicted)
• Appearance: /
• Density: 1.071±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Dichloromethane
• PKA: 14.87±0.10(Predicted)
• CAS DataBase Reference: 3-(4-Methoxybenzyloxy)-1-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methoxybenzyloxy)-1-propanol(135362-69-5)
• EPA Substance Registry System: 3-(4-Methoxybenzyloxy)-1-propanol(135362-69-5)

Safety Data

• Hazardous Substances Data: 135362-69-5(Hazardous Substances Data)

Usage

Description

3-(4-Methoxybenzyloxy)-1-propanol, also known as 3-[(4-Methoxybenzyl)oxy]propan-1-ol, is an organic compound that serves as a crucial intermediate in the synthesis of various chemical compounds. It is characterized by its molecular structure, which includes a propanol backbone with a methoxybenzyloxy group attached to the third carbon.

Uses

Used in Pharmaceutical Industry:
3-(4-Methoxybenzyloxy)-1-propanol is used as an intermediate in the synthesis of Aflatoxin G2-d3 (A357487), also known as Labelled Aflatoxin G2. Aflatoxins are a group of highly carcinogenic mycotoxins produced as secondary metabolites by certain fungal species, such as Aspergillus flavus or Aspergillus parasiticus. These fungi can grow on a variety of foods, including peanuts, nuts, spices, and cereals, posing a significant health risk due to their hepatotoxic effects.
Used in Environmental and Food Contamination Control:
3-(4-Methoxybenzyloxy)-1-propanol plays a role in the detection and monitoring of environmental and food contaminants. Aflatoxins, which this compound is involved in synthesizing, are a major concern in the food industry due to their potential to cause severe health issues. By synthesizing labelled aflatoxins, it is possible to develop detection methods and control measures to ensure the safety and quality of the food supply.

Upstream product

• 5689-71-4 2-(4-methoxy-phenyl)-[1,3]dioxane 
• 105-13-5 4-Methoxybenzyl alcohol 
• 504-63-2 trimethyleneglycol 
• 623-12-1 4-chloromethoxybenzene 
• 88023-78-3 para-methoxybenzyl chloride 
• 152944-16-6 1-methoxy-4-(3-(4-methoxybenzyloxy)propoxy)benzene 
• 123-11-5 4-methoxy-benzaldehyde 
• 2746-25-0 p-Methoxybenzyl bromide 
• 824-94-2 p-methoxybenzyl chloride 
• 89238-99-3 O-(4-methoxybenzyl)-trichloroacetimidate 

Downstream Products

• 154366-13-9 (+/-)-6-(4'-methoxyphenylmethoxy)-1,2-hexadien-4-ol 
• 154366-14-0 (+/-)-6-(4'-methoxyphenylmethoxy)-4-(t-butyldimethylsilyloxy)-1,2-hexadiene 
• 154366-12-8 (+/-)-1-(4'-methoxyphenylmethoxy)-6-(tetrahydropyran-2'-yloxy)-4-hexyn-3-ol 
• 152944-16-6 1-methoxy-4-(3-(4-methoxybenzyloxy)propoxy)benzene 
• 1226985-26-7 (+/-)-5-(4-methoxybenzyloxy)pent-1-en-3-ol 
• 1352739-31-1 5-[(4-methoxybenzyl)oxy]pent-1-en-3-one 
• 1352739-37-7 (E)-methyl 2-(2-(3-((tert-butyldimethylsilyl)oxy)-9-((4-methoxybenzyl)oxy)-2-methyl-7-oxonon-5-en-2-yl)thiazol-4-yl)acetate 
• 158817-23-3 (2R,3R)-5-p-methoxybenzyloxy-3-methylpentane-1,2-diol 
• 1005776-31-7 (E)-ethyl-3-((2S,3S)-3-(2-(4-methoxybenzyloxy)ethyl)oxiran-2-yl)acrylates 
• 1376666-11-3 (4R,5S,E)-ethyl-5-hydroxy-7-(4-methoxybenzyloxy)-4-methylhept-2-enoate 
• 1376666-13-5 C₂₂H₃₈O₄Si 
• 1376666-15-7 C₂₂H₃₆O₄Si 
• 1376666-17-9 C₂₆H₄₂O₅Si 
• 1376666-04-4 C₂₃H₂₅F₃O₆ 

Relevant articles and documents

NUCLEOSIDE PRODRUGS AND USES RELATED THERETO

Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω -oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.

Total Synthesis and Structure Revision of Halioxepine

The first total synthesis of halioxepine is accomplished using a 1,4-addition for constructing the quaternary center at C10 and a halo etherification for the generation of the tertiary ether at C7. The correct structure of halioxepine was determined by assembling different enantiomeric building blocks and by changing the relative configuration between C10 and C15.

Modular Total Synthesis of iso-Archazolids and Archazologs

Full details on the design, development, and successful implementation of suitable synthetic strategies directed toward the total synthesis of iso-archazolids and archazologs are reported. Both a biomimetic and a multistep total synthesis of iso-archazolid B, the most potent and least abundant archazolid, are described. The bioinspired conversion from archazolid B was realized by a high-yielding 1,8-Diazabicyclo[5.4.0]undec-7-ene catalyzed one-step double-bond shift. A highly stereoselective total synthesis was accomplished in 25 steps, involving a sequence of highly stereoselective aldol reactions, an efficient aldol condensation to forge two elaborate fragments, and a challenging ring-closing metathesis macrocyclization with an unusual Stewart-Grubbs catalyst. These strategies proved to be generally useful and could be successfully implemented for the preparation of three novel iso-archazolids as well as five novel archazologs, lacking the thiazole side chain. A wide variety of further archazolids and archazologs may now be targeted for exploration of the promising anticancer potential of these polyketide macrolides.